The Infectious Diseases Society of America (IDSA) has named Robert T. “Chip” Schooley, MD, FIDSA, to be editor-in-chief of the Society’s prestigious peer-reviewed journal Clinical Infectious Diseases (CID)
. Dr. Schooley’s term will begin in January 2017, upon the retirement of the journal’s current editor-in-chief, Sherwood Gorbach, MD, FIDSA, who has led the journal with distinction since 2000. Ferric C. Fang, MD, will serve as CID
’s next deputy editor-in-chief.
Published since 1979, CID is a leading journal in the field of infectious diseases with a broad international readership. The journal publishes articles on a variety of subjects of interest to practitioners and researchers. Topics range from clinical descriptions of infections, public health, microbiology, and immunology to the prevention of infection, the evaluation of current and novel treatments, and the promotion of optimal practices for diagnosis and treatment.
Dr. Schooley was selected as editor-in-chief after a comprehensive search that generated numerous applications from highly qualified candidates. Currently, he serves as professor and head of the Division of Infectious Diseases of the University of California, San Diego (UCSD). He has served as an associate editor of CID for the past decade.
Dr. Schooley’s initial training in medicine was at the Johns Hopkins Hospital, followed by sequential infectious disease fellowships at the National Institute of Allergy and Infectious Diseases (NIAID) and at the Massachusetts General Hospital (MGH), where he joined the faculty of Harvard Medical School. In 1990, he became chief of the Division of Infectious Diseases at the University of Colorado, where he developed an integrated HIV research and clinical care program. Dr. Schooley led the NIAID’s AIDS Clinical Trials Group (ACTG) from 1995 through 2002, during which time the ACTG played a central role in the development of contemporary HIV management. He was the founding chair of the Conference on Retroviruses and Opportunistic Infections (CROI) and continues to play a central role in guiding this meeting. After stepping down from ACTG, Dr. Schooley refocused his research interests on extending antiretroviral therapy to resource-limited sessions and on the emerging area of hepatitis C virus (HCV) drug discovery and development. He served as a founding member of the American Association for the Study of Liver Disease/IDSA HCV Treatment Guidance Panel.
Dr. Schooley’s laboratory at UCSD conducts studies in HCV drug discovery, P. falciparum interactions with HIV, influenza and novel point of care diagnostics development. He is an active clinician and serves as an ID consultant on the Inpatient Infectious Disease services of the UCSD Medical Center and as an attending physician on the Internal Medicine Service. He also has an outpatient practice in which he provides care to HCV infected patients.
“We are fortunate to have identified such a distinguished physician as Dr. Schooley to provide editorial leadership and continue the legacy of the many renowned physicians who have served in this capacity,” said Louis D. Saravolatz, MD, FIDSA, chair of the IDSA Publications Committee and CID Editor Search Work Group.
As incoming editor-in-chief, Dr. Schooley inherits an extremely strong journal. CID’s current impact factor is 8.886 and it ranks 2 out of 78 journals in the infectious diseases category for the 10th consecutive year. “CID outstrips competitors because of its emphasis on fair, transparent and rapid review and careful selection of novel material of relevance to those with interest in clinical and translational topics in infectious diseases and public health,” said Dr. Schooley. His goals for CID include anticipating new areas of science, recognizing the global importance of the field, embracing new publication technologies and novel media, and supporting the clinical missions of the ID specialty.
Dr. Schooley is currently establishing his editorial team and has already named Dr. Fang to be CID
’s deputy editor-in-chief. Dr. Fang received his undergraduate and medical education at Harvard, and obtained postgraduate training in internal medicine and infectious diseases at UCSD. He has worked as an academic clinician-scientist-educator at the University of Colorado (1992-2001) and the University of Washington (2001-present), where he currently holds an appointment as Professor of Laboratory Medicine, Microbiology and Medicine.
“Ferric’s experience as an infectious diseases clinician, clinical microbiologist, educator, researcher and journal editor-in-chief have provided him with excellent preparation to take on this new role at CID,” said Dr. Schooley.
While in Colorado, Dr. Fang directed the Clinical Microbiology Laboratory at the university hospital, where he developed a strong appreciation for the importance of diagnostic microbiology in ID practice. At UW, his primary clinical responsibility has been to direct the Clinical Microbiology Laboratory at Harborview Medical Center. Meeting thrice-weekly with the ID consult team and reviewing culture and clinical data for every patient coming through the hospital has provided him with an unusually broad clinical perspective, which is directly relevant to CID. His research has focused on bacterial pathogenesis and the molecular diagnosis of infections, and his research laboratory has made fundamental contributions concerning the role of nitric oxide in host defense, the pathogenesis of Salmonella and staphylococcal infections, the evolution of bacterial transcriptional regulatory networks, and the development of novel molecular diagnostic methods for conditions such as Clostridium difficile colitis. Dr. Fang is the founding Director of the UW Interdisciplinary Training Program in Bacterial Pathogenesis. He recently was appointed to a task force of the Clinical Laboratory Standards Institute (CLSI) charged with updating antimicrobial susceptibility guidelines to incorporate emerging molecular technologies.
Dr. Fang has served as editor-in-chief of the American Society for Microbiology journal Infection and Immunity since 2007 and his term will end in 2017. He has been a member of the IDSA since starting his fellowship in 1987, has been an invited speaker at numerous IDSA meetings, has served as a reviewer for CID and The Journal of Infectious Diseases, and has served on the IDSA Standards and Practice Guidelines Committee.
“With wise stewardship, CID is well positioned to continue its role as the preeminent journal in the field,” said Dr. Fang. “It is a great honor to be named part of the CID team.”
< Previous Article | Next Article >